IDRA-21 10 MG kúlur
IDRA-21 Pellets properties
Samheiti 7-klór-3-metýl-3,4-díhýdró-2H-1,2,4-bensótíadíasín 1,1-díoxíð
CAS Fjöldi : 22503-72-6
Formúla C8H9ClN2O2S
Mólmassi : 232,6 g/mól
Hreinleiki : >97%
€13.50 – €398.58Verðbil: €13.50 til €398.58
* Upplýsingarnar á þessari síðu eru samantekt og eru ekki ætlaðar til að ná yfir allar tiltækar upplýsingar um þetta lyf. Þær fjalla ekki um alla mögulega notkun, leiðbeiningar, varúðarráðstafanir, milliverkanir lyfja eða aukaverkanir og koma ekki í stað sérfræðiþekkingar og mats heilbrigðisstarfsmanns.
IDRA-21 10 MG Pellets – Scientific Description & User Manual
Vörulýsing
IDRA-21 (10 mg kúlur) is a potential AMPA receptor potentiator belonging to the class of nootropic and neuroprotective research chemicals . It works by enhancing glutamate-induced signaling in the brain, which may lead to improved cognitive function, neuroplasticity, and potentially neurorecovery.
Þessar kúlur eru highly pure (≥98%) , standardized dosed and intended solely for scientific research and preclinical studies .
Uses & Applications
IDRA-21 is being studied for its possible effects on:
Cognitive Enhancement – May increase alertness, learning ability, and memory consolidation.
Neuroprotection – Potential protective effect in neurodegenerative diseases (e.g. Alzheimer’s, stroke).
Neurological Recovery – May Promote Synaptic Plasticity After Brain Injury.
Scientific Research – Study of AMPA receptor modulation and glutamate signaling.
⚠ Not approved for human or veterinary use – For in vitro and controlled preclinical studies only.
Dosage & Safety Guidelines
Investigational dosage (in vitro/preclinical): 5–20 mg/kg (depending on model).
Pellet Solution: Can be dissolved in distilled water or DMSO for experiments.
Stjórnsýsla: Orally (animal models) or directly in cell cultures.
Frequency: Single dose for acute effect; long-term studies require careful monitoring.
🚨 NB:
No human application – No safety data for human use.
High doses may cause neuroexcitotoxicity.
Avoid combination with other glutamate modulators.
Ókostir og áhætta
Overstimulation of neurons (risk of excitotoxicity in case of overdose).
Möguleg kvíði eða æsingur in susceptible models.
Takmarkaðar langtímaupplýsingar on tolerance and adverse effects.
Not suitable for chronic use without extensive toxicity studies.
Algengar spurningar (FAQs)
1. Is IDRA-21 legal in the Netherlands?
Yes, but only for vísindarannsóknir . It doesn’t fall under the Opium Act, but it’s also not approved as a medicine.
2. How exactly does IDRA-21 work?
It enhances the AMPA receptor response , making glutamate signaling longer and more intense. This can lead to improved synaptic communication.
3. Can IDRA-21 be compared to other nootropics?
It has a unique mechanism of action, but similar targets as racetams or ampakines (e.g. Sunifiram).
4. Are there any known interactions?
NMDA antagonists (e.g. memantine) – Potentially adverse effects.
GABAergic agents (e.g., benzodiazepines) – May reduce anxiolytic effects.
Rannsóknarskýrsla og gæðaeftirlit
HPLC analysis: ≥98% purity .
No detectable heavy metals or solvent residues .
Homogeneous pellet formulation for consistent dosing.
Batch certification available for research institutions.
Ráðlagðar rannsóknarsviðsmyndir
Cognitive studies – Effects on memory and learning in animal models.
Neuroprotective research – Potential role in ischemic injury (stroke models).
Raflífeðlisfræði – AMPA receptor response measurements in neuronal cultures.
🔬 For controlled laboratory use only – No recreational use!
